Panel Discussion: Accelerating the Use of MRD as a Surrogate Endpoint Across Indications
9:30 am - Thursday 5th February 2026
- Leveraging existing MRD evidence from hematology (e.g. multiple myeloma) to inform regulatory and policy pathways in new settings
- Driving alignment on assays, thresholds, endpoints, and timepoints to ensure cross-study comparability and reproducibility
- Building collaborative frameworks and secure data-sharing models to generate the robust evidence required by regulators and payers
